SciSparc, Clearmind Medicine deal leads to publication of ketamine combo

SciSparc (SPRC) announces that as part of its ongoing collaboration with Clearmind Medicine (CMND) a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has announced the publication of its patent application under the international Patent Cooperation Treaty, for innovative combinations of ketamine and N-acylethanolamines. SciSparc and Clearmind, as part of their collaboration, research combination treatment comprised of SciSparc’s Palmitoylethanolamide PEA and Clearmind’s innovative psychedelic molecule, MEAI, for treating addictions, weight loss and mental health disorders. Furthermore, SciSparc and Clearmind are jointly exploring new treatments based on psychedelic molecules and PEA. To date, thirteen patents related to this collaboration have been filed with the U.S. Patent and Trademark Office and several other global patent offices…The approved treatment comes with strict usage guidelines. It must be administered only at certified medical facilities and used alongside an antidepressant medication. After receiving a dose, patients are required to remain at the facility for a two-hour observation period. This allows healthcare providers to monitor for any potentially serious side effects that may occur.